Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short term Debt (2020 - 2022)

Anika Therapeutics (ANIK) has disclosed Short term Debt for 7 consecutive years, with $4.3 million as the latest value for Q2 2022.

  • On a quarterly basis, Short term Debt fell 74.42% to $4.3 million in Q2 2022 year-over-year; TTM through Jun 2022 was $4.3 million, a 74.42% decrease, with the full-year FY2021 number at $4.3 million, down 67.04% from a year prior.
  • Short term Debt was $4.3 million for Q2 2022 at Anika Therapeutics, roughly flat from $4.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $24.8 million in Q1 2021 to a low of $4.3 million in Q3 2021.
  • A 3-year average of $10.3 million and a median of $4.3 million in 2021 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: crashed 67.04% in 2021, then crashed 82.68% in 2022.
  • Anika Therapeutics' Short term Debt stood at $13.1 million in 2020, then tumbled by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • Per Business Quant, the three most recent readings for ANIK's Short term Debt are $4.3 million (Q2 2022), $4.3 million (Q1 2022), and $4.3 million (Q4 2021).